HER2-positive cancer is aggressive, but it’s also one of the most treatable forms of cancer today. That might sound contradictory, but it captures the reality: HER2-positive tumors grow faster than many other types, yet the targeted therapies available for them have dramatically improved survival over the past two decades. Whether this status is “good” or “bad” depends heavily on the stage at diagnosis and how the cancer responds to treatment.
What HER2-Positive Means
HER2 is a protein that sits on the surface of cells and sends signals telling them to grow and divide. Every cell has some HER2, but in HER2-positive cancers, the cells have far too much of it. This excess protein drives the cells to multiply much faster than normal. In the early 1980s, researchers demonstrated that the HER2 protein could cause normal cells to grow uncontrollably like aggressive cancer cells.
About 15 to 20 percent of breast cancers are HER2-positive. The protein also plays a role in other cancers: roughly 15 percent of advanced stomach cancers and 30 percent of advanced cancers at the junction between the stomach and esophagus are HER2-positive. It can also appear in lung, bladder, and other solid tumors.
Why It Was Once Considered Bad News
Before targeted treatments existed, a HER2-positive diagnosis was one of the worst outcomes a breast cancer patient could receive. These tumors grew faster, were more likely to spread, and had higher recurrence rates than most other breast cancer subtypes. Chemotherapy alone couldn’t effectively counteract the growth signals the HER2 protein was sending. Patients with HER2-positive disease had significantly shorter survival times compared to those with HER2-negative cancers.
Why the Outlook Has Changed
The development of drugs that specifically block HER2 transformed this subtype from one of the most dangerous into one of the most targetable. The key insight was simple: if a specific protein is driving the cancer, a drug that blocks that protein can shut it down. The first of these drugs, trastuzumab (Herceptin), arrived in the late 1990s and cut recurrence rates roughly in half for early-stage patients.
Today, the FDA has approved multiple HER2-targeted therapies, including trastuzumab, pertuzumab, and newer antibody-drug conjugates like trastuzumab deruxtecan (Enhertu). These work in different ways. Some block HER2 from sending growth signals. Others attach a chemotherapy payload directly to the HER2 protein, delivering cancer-killing drugs straight into the tumor cell while sparing more healthy tissue. This growing arsenal means that if one treatment stops working, others are available.
Trastuzumab deruxtecan has been particularly significant because it works not only in traditional HER2-positive cancers but also in tumors with lower levels of HER2, a category now called “HER2-low.” This has opened up targeted treatment to patients who were previously considered HER2-negative and had no access to these drugs.
Survival Rates by Stage
Current five-year survival statistics from the National Cancer Institute’s SEER database (2016 to 2022) show how much outcomes have improved. For HER2-positive breast cancer that also has hormone receptors (the most common combination):
- Localized (hasn’t spread beyond the breast): 99.5 percent five-year survival
- Regional (spread to nearby lymph nodes): 91.5 percent
- Distant (spread to other organs): 48.7 percent
For HER2-positive cancers that lack hormone receptors, the numbers are slightly lower but still strong:
- Localized: 97.8 percent
- Regional: 86.4 percent
- Distant: 43.1 percent
These figures reflect outcomes across all patients diagnosed during that period, including those diagnosed years ago with older treatments. Patients starting treatment today with the latest therapies may do better than these numbers suggest.
HER2-Positive in Stomach and Other Cancers
In stomach and gastroesophageal junction cancers, HER2-positive status carries similar implications: the cancer is aggressive, but targeted therapy helps. A landmark clinical trial showed that adding trastuzumab to chemotherapy substantially improved how long people with these cancers lived. It was the first study in decades to show a survival improvement in advanced stomach cancer and quickly became the standard approach.
More recent trials have combined HER2-targeted therapy with immunotherapy for these patients. In people whose tumors had high levels of a protein called PD-L1, this combination extended median overall survival from about 15.7 months to 20.0 months. Trastuzumab deruxtecan has also been approved for HER2-positive stomach, esophageal, and lung cancers, as well as for HER2-positive solid tumors anywhere in the body.
What Treatment Looks Like
HER2-targeted drugs are typically given as infusions, often alongside chemotherapy, especially in the early stages of treatment. For early-stage breast cancer, treatment usually lasts about a year. Many patients receive a combination of targeted drugs before surgery to shrink the tumor, then continue targeted therapy afterward to reduce recurrence risk. For advanced or metastatic cancer, treatment continues as long as it’s working and side effects remain manageable.
One side effect specific to HER2-targeted drugs is the potential for heart-related problems. These therapies can cause the heart’s pumping ability to decrease, which shows up as a drop in the heart’s ejection fraction on imaging tests. This is usually asymptomatic and often reversible when caught early, which is why patients receiving these drugs get regular heart monitoring throughout treatment. Clinical heart failure occurs less commonly. Newer HER2-targeted agents appear to carry a lower cardiac risk than trastuzumab.
How HER2 Status Is Determined
HER2 status is determined through testing on a tissue sample from the tumor, usually from a biopsy. The initial test looks at how much HER2 protein is present on the cell surface, scored on a scale from 0 to 3+. A score of 3+ means the cancer is HER2-positive. A score of 0 means it’s negative. Scores of 1+ or 2+ fall in between and may require a second test that looks at the HER2 gene itself to determine whether it’s amplified.
The category of “HER2-low” (scores of 1+ or 2+ without gene amplification) has become clinically meaningful in recent years. These tumors were previously grouped with HER2-negative cancers and weren’t eligible for targeted therapy. Now, patients with HER2-low metastatic breast cancer can receive trastuzumab deruxtecan, which represents a significant expansion of treatment options for a large group of patients.
The Bottom Line on Good vs. Bad
HER2-positive status is neither purely good nor purely bad. The biology is aggressive, with faster-growing tumors and a higher natural tendency to spread. But that same biology provides a clear, effective target for treatment. Patients diagnosed with early-stage HER2-positive breast cancer today have survival rates above 90 percent, numbers that would have been hard to imagine 30 years ago. Even in advanced disease, the growing number of targeted options continues to extend survival and improve quality of life. The presence of HER2 gives oncologists a specific vulnerability to exploit, and the drugs available to do so are among the most effective in all of cancer medicine.